



KAMUYU AYDINLATMA PLATFORMU

EİS ECZACIBAŞI İLAÇ SİNAİ VE FİNANSAL YATIRIMLAR SANAYİ VE TİCARET A.Ş. Non-current Financial Asset Sale

Summary

Completion of the process of the sale of our shares representing 50% of the share capital of Eczacıbaşı-Monrol



**MERKEZİ KAYIT
İSTANBUL**
Türkiye Sermaye Piyasası - Merkezi
Saklama ve Veri Depolama Kuruluşu

Non-Current Financial Asset Sale

Related Companies []

Related Funds []

Non-Current Financial Asset Sale	
Update Notification Flag	Evet (Yes)
Correction Notification Flag	Hayır (No)
Date Of The Previous Notification About The Same Subject	05.04.2024, 08.08.2024, 23.12.2024, 21.02.2025, 21.03.2025
Postponed Notification Flag	Hayır (No)
Announcement Content	
Board Decision Date for Sale	05/04/2024
Were Majority of Independent Board Members' Approved the Board Decision for Sale?	Yes
Title of Non-current Financial Asset Sold	Eczacıbaşı Monrol Nükleer Ürünler Sanayi ve Ticaret A.Ş.
Field of Activity of Non-current Financial Asset Sold	Operating in health sector,manufacturing,import and distribution of radiopharmaceuticals used in nuclaer medicine
Capital of Non-current Financial Asset Sold	67.500.000 TL
Date on which the Transaction was/will be Completed	27.03.2025
Sales Conditions	Peşin (Cash)
Nominal Value of Shares Sold	33.750.002 TL
Sales Price Per Share	2,13 Euro, subject to changes based on closing adjustments.
Total Sales Value	71.766.263,34 Euro, subject to changes based on closing adjustments.
Ratio of Shares Sold to Capital of Non-current Financial Asset (%)	50
Total Ratio of Shares Owned in Capital of Non-current Financial Asset After Sales Transaction (%)	0 (Our Company no longer holds any shares in Eczacıbaşı- Monrol's capital)
Total Voting Right Ratio Owned in Non-current Financial Asset After Sales Transaction (%)	0
Ratio of Non-current Financial Asset Sold to Total Assets in Latest Disclosed Financial Statements of Company (%)	0,73
Ratio of Transaction Value to Sales in Latest Annual Financial Statements of Company (%)	34
Since Eczacıbaşı Monrol Nükleer Ürünler Sanayi ve Ticaret A.Ş. is included in the consolidated financial statements of our Company by the equity method, the contemplated sale of financial fixed assets is not	

Effects on Company Operations	expected to have a significant impact on our Company's activities and turnover. Following this share transfer, our partnership will continue its activities in the pharmaceutical sector through its affiliates, EİP Eczacıbaşı İlaç Pazarlama A.Ş. and Gensenta İlaç Sanayi ve Ticaret A.Ş. On the other hand, the cash generated from the sale will strengthen the Company's cash position.
Profit / Loss Arised After Transaction	It is expected that a pre-tax profit of approximately 2,5 billion TL will be generated from the sale, and the final profit amount, after closing adjustments, can be tracked from the Company's financial statements for the relevant period.
How will Sales Profit be Used if Exists?	At present, no specific allocation has been made for the use of profits, and it will be evaluated according to the circumstances.
Board Decision Date for Use of Sales Profit if Exists	-
Title/ Name-Surname of Counter Party Bought	Curium International Trading B.V.
Is Counter Party a Related Party According to CMB Regulations?	Hayır (No)
Relation with Counter Party if any	Within the framework of capital markets legislation, the counterparty has no direct or indirect relationship with our Company in terms of management, audit, or capital.
Agreement Signing Date if Exists	05/04/2024
Value Determination Method of Non-current Financial Asset	Bargaining Procedure.
Did Valuation Report be Prepared?	Düzenlenmedi (Not Prepared)
Reason for not Preparing Valuation Report if it was not Prepared	There is no mandatory obligation under the applicable legislation
Date and Number of Valuation Report	-
Title of Valuation Company Prepared Report	-
Value Determined in Valuation Report if Exists	-
Reasons if Transaction wasn't/will not be performed in Accordance with Valuation Report	-
Explanations	

In our announcement dated 05.04.2024, it was stated that a Share Transfer Agreement had been signed regarding the purchase of our 33.750.002 shares, corresponding to 50% of Eczacıbaşı Monrol Nükleer Ürünler Sanayi ve Ticaret A.Ş.'s (Eczacıbaşı-Monrol) paid-in capital, by Curium International Trading B.V. It was also noted that the completion of the share transfer was subject to obtaining the necessary permits and approvals, including the approval of the Competition Authority, as well as the fulfillment of all agreed closing conditions.

Following the approval of the Competition Authority and the fulfillment of all closing conditions, the share transfer and payment transactions related to the sale have been completed as of 27.03.2025 (today). The total share transfer price, determined as 71.766.263,34 Euros for the transferred shares, will be subject to closing adjustments based on financial debt, financial debt-like items, cash, and working capital as reflected in the independently audited financial statements prepared as of the closing date.

*Total share transfer price does not include the contingent performance payments.

**TL amounts have been calculated based on the average of the Central Bank of Turkey's (CBRT) buying and selling exchange rates announced on the day prior to the payment date.

This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.

We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.